The short of it
- On July 1, 2026 the FDA pushed Casgevy (exagamglogene autotemcel) down to children 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, the first gene-editing therapy any regulator has cleared for this age group.
- It uses CRISPR to release a genetic brake that normally silences fetal hemoglobin, so a child’s red cells stop sickling. One treatment, built from the child’s own stem cells.
- In the pediatric data almost every evaluable child hit the target, no severe pain crises or freedom from transfusions, and roughly 5,500 more US children now qualify.
What Casgevy actually does
Start with the mechanism, because a lot of the coverage muddles it. Casgevy does not slot a healthy gene into a child. It takes a brake off.
We all make fetal hemoglobin as babies. Then a genetic switch called BCL11A flips it off, and adult hemoglobin takes over, which in sickle cell is the defective kind that warps red cells into their sickle shape. Casgevy harvests a child’s own blood stem cells and uses CRISPR to disable that switch. With the brake gone, the cells go back to making fetal hemoglobin, and fetal hemoglobin does not sickle. After chemotherapy clears out the old marrow, the edited cells are infused back. Once, and it is done.
That conditioning chemo is no aside. It is punishing, and it is the reason this is a hospital-scale undertaking rather than something you pick up at a pharmacy.
Why reaching a two-year-old is the point
Sickle cell does its damage early and out of sight. Well before the frightening pain crises begin, the deformed cells are already scraping at organs. So dropping the approval age from 12 to 2 follows a blunt logic: intervene before the cumulative harm hardens.
Megha Kaushal, MD, MSc, acting deputy director of CBER’s Office of Therapeutic Products, framed it exactly that way, saying earlier treatment lowers the risk of lasting end-organ damage and that reaching younger patients opens a critical window for intervention. The 5,500 newly eligible US children are the group inside that window.
What the evidence for younger kids looks like
The FDA did not launch a brand-new trial in toddlers. It took results from children aged 5 to under 12 and extended the reasoning down to age 2, since the biology of the edit does not change with age. The numbers are small but unusually clean:
- Sickle cell (ages 5 to under 12): of 11 enrolled, 8 were evaluable, and all 8 went a full 12 straight months with zero severe pain crises within two years.
- Beta thalassemia (ages 5 to under 12): of 15 enrolled, 9 were evaluable, and 8 of those 9 became transfusion-independent for at least 12 months, a median of about 20.1 months.
Every evaluable sickle cell child cleared the bar. In thalassemia, all but one walked away from transfusions.
The fine print families should weigh
A one-and-done, cure-like result is the headline, and it is real. So is the fine print. The most common adverse reactions were mucositis and febrile neutropenia, with decreased appetite in the sickle cell group. The label also flags engraftment failure, slow platelet recovery, hypersensitivity, and the theoretical chance of off-target edits somewhere CRISPR was never pointed.
For a family watching a small child cycle through crisis after crisis, none of that cancels the pull of this option. It just makes the choice a genuine one, set against a disease that, left to run, keeps doing its own quiet damage year after year.
Sources:
- Vertex Pharmaceuticals, “FDA Approval for Expanded Use of CASGEVY in People Ages 2 and Older”
- Healio, “FDA expands Casgevy approval to children 2 years and older with sickle cell disease”
- HCPLive, “FDA Expands Exa-Cel Gene Therapy Approval to Children 2 Years and Up”
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.